Cargando…
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression
Dependence on the 26S proteasome is an Achilles’ heel for triple-negative breast cancer (TNBC) and multiple myeloma (MM). The therapeutic proteasome inhibitor, bortezomib, successfully targets MM but often leads to drug-resistant disease relapse and fails in breast cancer. Here we show that a 26S pr...
Autores principales: | Banerjee, Sourav, Wei, Tiantian, Wang, Jue, Lee, Jenna J., Gutierrez, Haydee L., Chapman, Owen, Wiley, Sandra E., Mayfield, Joshua E., Tandon, Vasudha, Juarez, Edwin F., Chavez, Lukas, Liang, Ruqi, Sah, Robert L., Costello, Caitlin, Mesirov, Jill P., de la Vega, Laureano, Cooper, Kimberly L., Dixon, Jack E., Xiao, Junyu, Lei, Xiaoguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900511/ https://www.ncbi.nlm.nih.gov/pubmed/31754034 http://dx.doi.org/10.1073/pnas.1912033116 |
Ejemplares similares
-
Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
por: Tandon, Vasudha, et al.
Publicado: (2022) -
Emerging roles of DYRK2 in cancer
por: Tandon, Vasudha, et al.
Publicado: (2021) -
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2
por: Banerjee, Sourav, et al.
Publicado: (2018) -
Dual inhibition of HSF1 and DYRK2 impedes cancer progression
por: Tandon, Vasudha, et al.
Publicado: (2023) -
Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer’s Disease
por: Hegde, Ashok N., et al.
Publicado: (2019)